A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones
mRUSTUS
1 other identifier
observational
173
1 country
4
Brief Summary
Early intervention attempts to shorten protracted delayed union (DU) or prevent non-union (NU) fractures are hampered by lack of validated quantitative assessment tools for bone fracture healing during normal and delayed healing processes. In actual practice, sequential X-rays usually follow a pre-determined time interval in patients with fractures.They constitute the best available state of the art used by surgeons to assess the fracture healing course. In an attempt to improve between raters reliability of radiographic assessment of healing, studies have explored a novel radiographic assessment for tibial shaft fractures, the Radiographic Union Scale for Tibial Fractures (RUST). The RUST assesses the presence of bridging callus and a fracture line on each of four cortices (seen on anterior-posterior and lateral views). This callus based scoring system has been since extended to other bones than the tibia in a retrospective case series. It has been renamed modified radiological union score (mRUS) and has shown potential value in bone healing measurement. Based on an initial retrospective study in nail-treated fractures, the first objective of the present investigation is to prospectively validate mRUS as a tool to identify patients at increased risk of DU and NU within the first 75-110 days after fracture occurrence. This prospective validation will be performed on a retrospective cohort of patients having sustained long bone fractures, including both upper and lower extremities. A further objective of the present investigation is to apply the scoring system to tomographic imaging in case of nail/plate treated fractures, deriving a tomographic union score (TUS) and first assess its potential value in bone healing for fractures treated by nails/plates.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2017
Shorter than P25 for all trials
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
September 15, 2017
CompletedFirst Posted
Study publicly available on registry
September 18, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 27, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
April 27, 2018
CompletedJune 11, 2020
June 1, 2020
8 months
September 15, 2017
June 9, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
mRUS assessed on X-Ray
75-110 days after fracture occurrence
Secondary Outcomes (1)
TUS assessed on CT-scan
75-110 days after fracture occurrence
Eligibility Criteria
Long bone fracture
You may qualify if:
- Male or female adult patient (\>18 and \< 80 years old)
- Patient with nail(s) (for mRUS validation study and TUS exploratory study) or plate(s) (for TUS exploratory study) treated long bone fractures, corresponding to the following OA/OTA classification: 11-A, 12-A, -B and -C, 13-A, 21-A, 22-A, -B and -C, , 31-A3, 32-A, -B and -C, 33-A 41-A2 and A3, 42-A, -B and -C and 43-A
- Patient for whom outcome of fracture is known
- For the mRUS validation study, patient with one follow up X-ray imaging performed 75-110 days after fracture occurrence
- For the TUS exploratory study, patient with one follow up CT-scan imaging performed 75-110 days after the fracture occurrence
You may not qualify if:
- Bone infection diagnosed between time of the fracture occurrence and the X-Ray or CT-scan imaging performed 75-110 days after the fracture occurrence
- Previous fracture and previous surgery on the fractured bone
- Bone tumour or history of bone tumour
- Bone metastasis
- Known evidence for ongoing metabolic bone disease (e.g. chronic renal failure, hyper or hypoparathyroidism, rickets, Paget's disease of bone, inherited or congenital bone abnormalities)
- Patient with current traumatic brain injury
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Investigating site DE01
Cologne, Germany
Investigating site DE03
Lübeck, Germany
Investigating site DE02
Munich, Germany
Investigating site DE04
Würzburg, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 15, 2017
First Posted
September 18, 2017
Study Start
September 1, 2017
Primary Completion
April 27, 2018
Study Completion
April 27, 2018
Last Updated
June 11, 2020
Record last verified: 2020-06